BioTrinity 2026

April 14-15, 2026
Convene, 133 Houndsditch, London EC3A 7BX, United Kingdom
Facebook
LinkedIn

SAVE THE DATES

BioTrinity 2026

Celebrating 20 Years of Catalysing Growth in Life Sciences.

We are excited to announce that our team will be attending BioTrinity 2026, OBN’s flagship life sciences conference, taking place on April 14-15, 2026 at 133 Houndsditch, London.

Now in its 20th year, BioTrinity has grown into one of the UK’s leading life science events, bringing together ~850 delegates from across the life sciences ecosystem, including academic entrepreneurs, emerging R&D companies, investors, big pharma, government, and international life science clusters.

Where

Convene, 133 Houndsditch, London EC3A 7BX, United Kingdom

When

April 14-15, 2026

Meet our team on site:

Marshal Ma – VP of Strategic Alliances & Business Development

Nadine Su – VP of Strategic Alliances & Business Development

What we offer

Integrated preclinical CRO services from discovery to IND

As a leading full-service preclinical CRO, we provide:

  • Drug discovery: target validation, structural biology, chemistry synthesis, hit-to-lead & lead optimization
  • Pharmaceutical development: API & formulation process development, quality and stability studies
  • Preclinical studies: pharmacokinetics, pharmacodynamics, and safety/toxicology (GLP-compliant with FDA, NMPA, OECD)

We also have dedicated platforms for next-generation modalities including ADCs, AOCs, PROTACs, mRNA vaccines, oligonucleotides, CGT, and AI‑driven drug discovery platform.

With global regulatory capabilities (FDA, NMPA, OECD), we support global IND filings and flexible collaboration models (FTE/FFS). To date, we have assisted 610+ IND applications receive clinical trial approval.

We’re eager to connect with partners, explore collaboration opportunities, and drive innovation in drug discovery & development together. See you in London!

BioTrinity 2026

Meet the Medicilon team by filling out the form below:

Name(Required)
Address(Required)

Search Medicilon

Preclinical CRO

Medicilon Webinar | IND-enabling Toxicity Studies, CTD Documentation and Translational Cardiac Risk Assessment

Preclinical CRO

Medicilon Stands Out at ASMS 2026: Only CRO Selected for Bioanalysis Zone’s ‘Pick of the Posters’

Preclinical CRO

Medicilon Congratulates Livzon Pharmaceutical on the Approval of LiYouBao® — China’s Only Export-Qualified r-FSH Injection Meeting Global International Standards

Contact Medicilon

Name(Required)
Address(Required)